Waters Corporation (Milford, Massachusetts) recently welcomed the University of Minnesota?s (Minneapolis, Minnesota) Mass Spectrometry Laboratory into its Centers of Innovation Program. Waters honored the Mass Spectrometry Laboratory under the direction of Joseph Dalluge for his research in diagnostic marker assay development relevant to cystic fibrosis and other diseases.
Waters Corporation (Milford, Massachusetts) recently welcomed the University of Minnesota’s (Minneapolis, Minnesota) Mass Spectrometry Laboratory into its Centers of Innovation Program. Waters honored the Mass Spectrometry Laboratory under the direction of Joseph Dalluge for his research in diagnostic marker assay development relevant to cystic fibrosis and other diseases. Dalluge also was honored for his research as a collaborating member of the university’s newly created Center for Bioanalysis of Molecular Signaling. The Dalluge mass spectrometry laboratory is part of the Department of Chemistry within the University’s College of Science and Engineering.
Dalluge’s research is focused on the use of leading edge liquid chromatograpy–mass spectrometry (LC–MS) instrumentation for metabolite profiling, biomarker discovery, and advanced assay development, as well as the detailed chemical characterization of biological systems as it relates to function.
Waters Centers of Innovation Program recognizes and supports the efforts of scientists facilitating breakthroughs in health and life science research, food safety, environmental protection, sports medicine, and other areas.
“I am honored to be a part of the Centers of Innovation Program and for what it means to us as we conduct leading-edge research. I regard Waters as more than just an instrument vendor of choice. They are a research partner,” said Dalluge.
Dalluge is one of 13 researchers recognized by Waters Centers of Innovation Program. Others include Jeremy Nicholson, Imperial College (London, England); John Engen, Northeastern University, (Boston, Massachusetts); James Scrivens, University of Warwick (Coventry, UK); David Cowan, Kings College (London, England); Arthur Moseley, Duke University (Durham, North Carolina); Julie Leary, University of California (Davis, California); Albert J. Fornace, Jr., Georgetown Lombardi Comprehensive Cancer Center (Washington, D.C.); Marcos Eberlin, University of Campinas (São Paulo, Brazil); Chang Hsu, Future Fuels Institute (Tallahassee, Florida); Ganesh Anund, National University of Singapore; Konstantinos Petritis, Translational Genomics Research Institute (Phoenix, Arizona); and Vladimir Shulaev, University of North Texas Department of Biological Sciences (Denton, Texas).
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.